BIIB vs. BMRN: Biogen vs. BioMarin Pharmaceutical Stock Comparison
How do Biogen (BIIB) and BioMarin Pharmaceutical (BMRN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Biogen (BIIB) and BioMarin Pharmaceutical (BMRN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BIIB | BMRN |
|---|---|---|
| Name | Biogen Inc. | BioMarin Pharmaceutical Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 36.71 billion USD | 10.85 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | September 17, 1991 | July 26, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIIB | BMRN |
|---|---|---|
| Total Return (1Y) | 65.44% | 8.82% |
| Total Return (3Y, Annualized) | 4.62% | -12.54% |
| Total Return (5Y, Annualized) | -0.96% | -7.51% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIIB | BMRN |
|---|---|---|
| Volatility (1Y, Annualized) | 34.58% | 35.50% |
| Beta (5Y) | 0.08 | 0.24 |
| Max Drawdown (5Y) | -64.35% | -57.64% |
| Avg. Volume (3M) | 1.05M | 2.28M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIIB | BMRN |
|---|---|---|
| Sharpe Ratio (1Y) | 1.77 | 0.13 |
| Sortino Ratio (1Y) | 2.77 | 0.23 |
Profitability
ROE (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Biogen (BIIB) reports 1.87%, ranking against industry peers normally.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.87%
- Max
- 109.18%
- Q3
- 6.23%
- BIIB
- 1.87%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Biogen (BIIB) reports 3.38%, ranking against industry peers normally.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.38%
- Max
- 18.05%
- Q3
- 4.78%
- BIIB
- 3.38%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Biogen (BIIB) at 24.12% and BioMarin Pharmaceutical (BMRN) at 26.58% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.12%
- Max
- 83.12%
- BIIB
- 24.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIIB | BMRN |
|---|---|---|
| ROE (TTM) | 1.87% | -0.31% |
| ROA (TTM) | 4.94% | 3.89% |
| Net Margin (TTM) | 3.38% | -0.52% |
| Operating Margin (TTM) | 24.12% | 26.58% |
| Gross Margin (TTM) | 75.77% | 53.21% |
Growth
Revenue Growth
Both Biogen (BIIB) at 2.22% and BioMarin Pharmaceutical (BMRN) at 12.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Biogen (BIIB) at -21.38% and BioMarin Pharmaceutical (BMRN) at -18.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | BIIB | BMRN |
|---|---|---|
| Revenue Growth (YoY) | 2.22% | 12.87% |
| Revenue Growth (3Y CAGR) | -0.94% | 15.40% |
| EPS Growth (YoY) | -21.38% | -18.55% |
| EPS Growth (3Y CAGR) | -25.04% | 33.89% |
Financial Strength
Current Ratio (MRQ)
Both Biogen (BIIB) at 1.95 and BioMarin Pharmaceutical (BMRN) at 2.44 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BIIB
- 1.95
- Min
- 0.10
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
Debt / Equity (MRQ)
Biogen (BIIB) at 0.41 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41
- Max
- 1.42
- Q3
- 0.65
- BIIB
- 0.41
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIIB | BMRN |
|---|---|---|
| Current Ratio (MRQ) | 1.95 | 2.44 |
| Debt / Equity (MRQ) | 0.41 | 0.67 |
| Net Debt / EBITDA | 1.97 | 4.04 |
Dividends
Dividend Yield (TTM)
Neither Biogen (BIIB) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Biogen (BIIB) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIIB | BMRN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Biogen (BIIB) trades at 107.51 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.51
- BIIB
- 107.51
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Biogen (BIIB) at 3.57 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.57
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIIB
- 3.57
- Q1
- 3.01
- Min
- 0.01
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Biogen (BIIB) at 1.94 and BioMarin Pharmaceutical (BMRN) at 1.73 are valued close to their industries’ norm against book — neither stands out from peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BIIB
- 1.94
- Q1
- 1.69
- Min
- -5.59
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIIB | BMRN |
|---|---|---|
| P/E Ratio (TTM) | 107.51 | -- |
| P/S Ratio (TTM) | 3.57 | 2.97 |
| P/B Ratio (MRQ) | 1.94 | 1.73 |
| Free Cash Flow Yield (TTM) | 2.20% | -0.15% |